ZEALAND PHARMA A/S financials

ZEALAND PHARMA A/S

Country: DK Reporting currency: DKK Latest annual report: 2026-06-30

LEI: 549300ITBB1ULBL4CZ12 ISIN: DK0060257814

Financial statements (DKK, as reported — unscaled; 78 line items across 3 annual periods)

Line item	2026	2025-12-31	2025-06-30
Income statement
Revenue	DKK 4.53B	—	DKK 9.10B
Cost of sales	DKK 0	—	DKK 1.0M
Gross profit	DKK 4.53B	—	DKK 9.10B
Operating expenses	DKK 1.20B	—	DKK 1.16B
Operating profit (EBIT)	DKK 3.32B	—	DKK 7.93B
Finance costs	DKK 80.0M	—	DKK 310.0M
Profit before tax	DKK 3.61B	—	DKK 7.77B
Income tax expense	DKK 89.0M	—	DKK 536.0M
Profit for the year	DKK 3.52B	—	DKK 7.24B
Total comprehensive income	DKK 3.52B	—	DKK 7.24B
Per share
Basic EPS	DKK 50.00	—	DKK 102.39
Diluted EPS	DKK 49.58	—	DKK 100.65
Free cash flow / share	DKK -4.07	—	DKK 111.33
Cash flow statement
Net cash from operating activities	-DKK 266.0M	—	DKK 8.02B
Net cash from investing activities	DKK 107.0M	—	-DKK 1.02B
Purchase of PP&E (capex)	DKK 23.0M	—	DKK 13.0M
Purchase of intangibles	DKK 2.0M	—	DKK 3.0M
Net cash from financing activities	-DKK 443.0M	—	-DKK 311.0M
Lease liability payments	DKK 17.0M	—	DKK 9.0M
Net change in cash	-DKK 602.0M	—	DKK 6.69B
Balance sheet
Total assets	DKK 19.76B	DKK 15.95B	—
Non-current assets	DKK 1.07B	DKK 279.0M	—
Property, plant & equipment	DKK 87.0M	DKK 70.0M	—
Right-of-use assets	DKK 81.0M	DKK 82.0M	—
Current assets	DKK 18.69B	DKK 15.67B	—
Trade & other receivables	DKK 3.82B	DKK 174.0M	—
Cash & equivalents	DKK 4.04B	DKK 4.58B	DKK 7.24B
Total equity	DKK 18.00B	DKK 14.83B	DKK 15.61B
Non-current liabilities	DKK 425.0M	DKK 453.0M	—
Long-term borrowings	DKK 312.0M	DKK 303.0M	—
Lease liabilities (non-current)	DKK 70.0M	DKK 80.0M	—
Current liabilities	DKK 1.34B	DKK 665.0M	—
Lease liabilities (current)	DKK 29.0M	DKK 23.0M	—
Derived metrics
Free cash flow	-DKK 289.0M	—	DKK 8.01B
Operating margin	73.4%	—	87.2%
Net margin	77.9%	—	79.6%
Return on equity	19.6%	—	46.4%
Cash conversion ratio	-0.08×	—	1.11×
Capex coverage	-11.57×	—	616.85×
Other reported items
Current Deferred Income Including Current Contract Liabilities	DKK 12.0M	DKK 65.0M	—
Current Derivative Financial Liabilities	DKK 69.0M	DKK 0	—
Current Financial Assets At Fair Value Through Profit Or Loss	DKK 10.42B	DKK 10.53B	—
Current Prepayments	DKK 299.0M	DKK 242.0M	—
Current Tax Assets Current	DKK 31.0M	DKK 31.0M	—
Current Tax Liabilities Current	DKK 87.0M	DKK 0	—
Deferred Tax Assets	DKK 1.0M	DKK 1.0M	—
Effect of Exchange Rate Changes On Cash and Cash Equivalents	DKK 63.0M	—	-DKK 170.0M
Equity and Liabilities	DKK 19.76B	DKK 15.95B	—
Finance Costs Paid Classified As Operating Activities	DKK 11.0M	—	DKK 8.0M
Finance Income	DKK 372.0M	—	DKK 153.0M
Finance Income Received Classified As Operating Activities	DKK 186.0M	—	DKK 100.0M
General and Administrative Expense	DKK 170.0M	—	DKK 135.0M
Increase Decrease In Working Capital	DKK 3.82B	—	-DKK 263.0M
Increase Decrease Through Exercise of Warrants Equity	DKK 12.0M	—	DKK 30.0M
Increase Decrease Through Sharebased Payment Transactions	DKK 73.0M	—	DKK 55.0M
Intangible Assets Other Than Goodwill	DKK 839.0M	DKK 45.0M	—
Issued Capital	DKK 72.0M	DKK 72.0M	—
Liabilities	DKK 1.76B	DKK 1.12B	—
Miscellaneous Other Operating Expense	DKK 0	—	DKK 196.0M
Noncurrent Derivative Financial Liabilities	DKK 43.0M	DKK 70.0M	—
Noncurrent Prepayments	DKK 45.0M	DKK 61.0M	—
Other Adjustments For Noncash Items	-DKK 145.0M	—	DKK 426.0M
Other Cash Receipts From Sales of Equity Or Debt Instruments of Other Entities Classified As Investing Activities	DKK 0	—	DKK 24.0M
Other Comprehensive Income Net of Tax Exchange Differences On Translation	-DKK 2.0M	—	DKK 1.0M
Other Current Payables	DKK 895.0M	DKK 230.0M	—
Other Current Receivables	DKK 87.0M	DKK 114.0M	—
Other Noncurrent Receivables	DKK 19.0M	DKK 20.0M	—
Payments To Acquire Or Redeem Entitys Shares	DKK 438.0M	—	DKK 332.0M
Proceeds From Exercise of Warrants	DKK 12.0M	—	DKK 30.0M
Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities	DKK 4.92B	—	DKK 7.70B
Purchase of Financial Instruments Classified As Investing Activities	DKK 4.79B	—	DKK 8.72B
Purchase of Treasury Shares	DKK 438.0M	—	DKK 332.0M
Research and Development Expense	DKK 985.0M	—	DKK 754.0M
Reserve of Exchange Differences On Translation	DKK 22.0M	DKK 24.0M	—
Retained Earnings	DKK 3.17B	DKK 6.0M	—
Sales and Marketing Expense	DKK 49.0M	—	DKK 79.0M
Share Premium	DKK 14.74B	DKK 14.73B	—
Trade and Other Current Payables To Trade Suppliers	DKK 245.0M	DKK 347.0M	—

Methodology

Every line item above is a fact tagged in ZEALAND PHARMA A/S's annual report filed in the European Single Electronic Format (ESEF) under the IFRS taxonomy (ifrs-full) — the income statement, balance sheet and cash-flow statement as the filer reported them. Values are shown as-is, in the reporting currency (DKK), without rescaling; the row labels map to the underlying concept name (e.g. Revenue → ifrs-full:Revenue, Operating profit → ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS → ifrs-full:DilutedEarningsLossPerShare), and any concept without a curated label is shown under “Other reported items” with its de-camel-cased tag name. Only consolidated, default-member facts are shown (segment / dimensional breakdowns are excluded).

“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.

Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.